Company Filing History:
Years Active: 1997-2005
Title: Olivier DeBacker: Innovator in Tumor Rejection Antigens
Introduction
Olivier DeBacker is a prominent inventor based in Brussels, Belgium. He has made significant contributions to the field of cancer research, particularly in the development of tumor rejection antigens. With a total of 5 patents to his name, his work has the potential to impact therapeutic approaches in oncology.
Latest Patents
DeBacker's latest patents include groundbreaking inventions related to isolated nucleic acid molecules that encode GAGE genes. One of his notable inventions is focused on nucleic acid molecules that encode members of the GAGE family of tumor rejection antigen precursors and their various uses. Another significant patent involves isolated, truncated nucleic acid molecules that code for GAGE tumor rejection antigen precursors. These innovations describe a new family of tumor rejection antigen precursors and their diagnostic and therapeutic applications.
Career Highlights
Olivier DeBacker is associated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research in cancer immunology. His work has garnered attention for its potential to enhance cancer treatment strategies through the use of tumor rejection antigens.
Collaborations
DeBacker has collaborated with notable colleagues in the field, including Benoit Van Den Eynde and Thierry R Boon-Falleur. These partnerships have contributed to the advancement of research in tumor rejection antigens and their applications in cancer therapy.
Conclusion
Olivier DeBacker stands out as an influential inventor in the realm of cancer research, with a focus on tumor rejection antigens. His innovative patents and collaborations highlight his commitment to improving therapeutic options for cancer patients.